Last reviewed · How we verify
Cyclobenzaprine with caffeine
Cyclobenzaprine is a muscle relaxant that reduces muscle tension through central nervous system depression, while caffeine is a stimulant that counteracts sedation and enhances alertness.
Cyclobenzaprine is a muscle relaxant that reduces muscle tension through central nervous system depression, while caffeine is a stimulant that counteracts sedation and enhances alertness. Used for Acute muscle spasm and musculoskeletal pain.
At a glance
| Generic name | Cyclobenzaprine with caffeine |
|---|---|
| Also known as | Miosan Caf® |
| Sponsor | EMS |
| Drug class | Skeletal muscle relaxant with CNS stimulant |
| Target | Alpha-2 adrenergic receptors (cyclobenzaprine); adenosine receptors (caffeine) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Cyclobenzaprine works as a centrally-acting skeletal muscle relaxant, likely through alpha-2 adrenergic receptor agonism and monoamine reuptake inhibition, reducing muscle spasm and tension. Caffeine is added as a stimulant to counteract the sedative effects of cyclobenzaprine, improving wakefulness and potentially enhancing analgesic efficacy through adenosine receptor antagonism.
Approved indications
- Acute muscle spasm and musculoskeletal pain
Common side effects
- Drowsiness
- Dizziness
- Dry mouth
- Headache
- Nervousness or jitteriness (from caffeine)
Key clinical trials
- Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment (PHASE3)
- A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclobenzaprine with caffeine CI brief — competitive landscape report
- Cyclobenzaprine with caffeine updates RSS · CI watch RSS
- EMS portfolio CI